Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20976850 | 0.96 | HRH3 (0.33) | HRH3L3MBTL3MBTD1L3MBTL1 | |
| SCHEMBL26760531 | 0.90 | HRH3 (0.33) | HRH3L3MBTL3MBTD1L3MBTL1 | |
| SCHEMBL12030661 | 0.88 | HRH3 (0.34) | HRH3TLR9TLR8TLR7KDM4E | |
| SCHEMBL24854350 | 0.88 | HRH3 (0.34) | HRH3TLR9TLR8TLR7KDM4E | |
| SCHEMBL13744835 | 0.88 | KDM4E (0.42) | HRH3TLR9TLR8TLR7KDM4E | |
| SCHEMBL23384368 | 0.88 | KDM4E (0.42) | HRH3TLR9TLR8TLR7KDM4E | |
| SCHEMBL12257648 | 0.86 | HRH3 (0.32) | HRH3 | |
| SCHEMBL25855521 | 0.84 | HRH3 (0.42) | HRH3 | |
| SCHEMBL24726517 | 0.83 | HRH3 (0.40) | HRH3TLR9TLR8TLR7L3MBTL3 | |
| SCHEMBL23384260 | 0.83 | HRH3 (0.40) | HRH3TLR9TLR8TLR7L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | HRH3 2159/4885TLR9 642/4885TLR8 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.